Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL.sure you did.
Show us a screen image of the transaction history of your trade.
Barely any 2s got tapped that day.
Good to finally see some positive company movement here.
I am not sure of the exact start date.
I noticed it on Jan 3. Using that date, you can say Jan 18 could be the last day of the grace period.
Do you have any past knowledge about the new COO and board member?
Will be nicer if they get current with their financials. They are now at risk of going to the Expert Market and being untradable if they don't release their overdue 3Q financials by mid month.
They will be renowned in the penny stock world for their creative writing of press releases.
Perhaps that should be their new business model.
Marketing and PRs for penny stock companies.
They might excel in that!
This PR is good for a few laughs.
Enjoy the use of colorful adjectives.
Is just like putting lipstick on a pig!
-----------------
Aluf Holdings Inc. Announces Exciting Developments in Biotech and BiometricsPress Release | 01/08/2024
FORT LAUDERDALE, FL., January 8, 2024 : Aluf Holdings, Inc., (OTC PINK: AHIX) a renowned player in the biometrics industry, is thrilled to announce significant strides in its operations and strategic focus. The company, known for its exceptional ability to identify and acquire innovative companies in the biometrics sector, is now leading the charge in industry transformations with a keen focus on groundbreaking technologies in both biotechnology and biometrics.
Currently, Aluf Holdings is poised to expand its portfolio with a number of major acquisitions, underscored by signed Letters of Intent (LOI). These acquisitions signal the commencement of a new era for Aluf Holdings, marked by a reimagined and rebranded approach geared towards acquiring more disruptive companies within the biotech sector.
These developments come at a time when the global biotech and biometric technology markets are experiencing robust growth. In 2022, the biometric market was valued at USD 34.27 billion, with projections suggesting a compound annual growth rate (CAGR) of 20.4% from 2023 to 2030; while the global biotechnology market, valued at $1.37 trillion in 2022, is projected to grow at a compound annual growth rate of 13.96% from 2023 to 2030. This growth underscores the vast opportunities in these sectors and aligns perfectly with Aluf Holdings strategic emphasis on biometrics and biotechnology.
Aluf Holdings stands at the forefront of shaping the future of healthcare, contributing to significant advancements in how diseases are diagnosed, and medical breakthroughs are achieved. The company's focus extends beyond financial success, aiming to make a tangible difference in the lives of individuals worldwide.
Investors and stakeholders are invited to join Aluf Holdings on this transformative journey as the company continues to acquire and nurture companies that have the potential to redefine industries and revolutionize lives. With its commitment to capturing bold and life-altering innovations, Aluf Holdings is set to make a profound impact in the realms of biotech and biometrics.
ENDV has stumbled into some quicksand today.
If it's less than 10K shares and not a AON order, it will not show up on L2.
It is not uncommon for the smaller orders that are not visible to be leapfrogged.
What's happening with itouch and PNNX?
No news for over a year.
I'm going to have assume, in my head, PNNX has merged with the CIA and can no longer share details about anything. LOL
As Sgt Shultz would say: ""I see nothing! I hear nothing! I know nothing!"
🚨 $ENDV
💰0.0085
Pink Current, AS: 2.5B, OS: 318M, US: 123M
Held at DTC Shares Updated:
🔴 108,493,901 (2023-12-15)
🟢 118,253,685 (2024-01-05)
Difference: +9.0% (+9.8M)
Restricted Shares Updated:
🔴 205,302,963 (2023-12-15)
🟢 195,543,179 (2024-01-05)
Difference: -4.8% (-9.8M)
Unrestricted Shares Updated:
🔴 113,448,634 (2023-12-15)
🟢 123,208,418 (2024-01-05)
Difference: +8.6% (+9.8M)
Since her shares are common...they are already counted in the outstanding shares you see on OTC Markets. She is listed on the 10Q due to owning more than 5% of the O/S.
She most likely purchased while it was on the Expert Market via a Canadian brokerage firm.
Her shares are common shares (not restricted).
We will only find out in the next ER....which will be released by April. Long wait for the 10K.
You can never have enough of a good thing! 😀
Even if she was selling them, the question is who is buying with no news released?
At least the selling is from Ask slapping and not Bid dumping.
Fantastic volume on no news but why is .019 being an endless number?
How many shares are hiding behind the 10k shown on L2....sigh.
It would be nice to have the one jackpot and walk away without the possibility of giving it back on another bad trade.
All one has to do is look at the 8K from 2018 regarding Magniant LLC and their sales pie in the sky projections which did not happen either.
One might blame Covid for the failure but there was a full year before Covid lockdown that should have produced sales per the 8K and it never happened as outlined.
8K released.
https://www.otcmarkets.com/filing/html?id=17161510&guid=1yJ-kWQN2-Y4B3h
Item 1.01 Entry into a Material Definitive Agreement.
On December 29, 2023, Endonovo Therapeutics, Inc. (“we”, “us” or the “Company”) entered into an amendment (the “Amendment”) to its May 2020 agreement with Evermed Medical Enterprise Ltd (“Evermed”) regarding the marketing of the Company’s SofPulse® device in Taiwan. The Amendment, among other things, establishes performance thresholds which Evermed must meet to maintain its exclusive rights in Taiwan under the Agreement. The Amendment sets forth quarterly sales thresholds for a six-year period beginning April 1, 2024. The thresholds increase during the six-year period from $8,400 in the first quarter of the first year to $2,856,000 in the last quarter of the sixth year and total $21,688,632 for the full six years. As reported in October 2023, the Taiwan Food and Drug Administration (“TFDA”), the regulatory division of the Ministry of Health and Welfare (“MOHW”) has approved the SofPulse® device for adjunctive treatment of pain and swelling (inflammation) after soft tissue surgery. We cannot guarantee that the payments provided for in the Amendment will actually be received by us.
Sofpulse is going to have some closer competition in the near future.
Biel RecoverRX is getting a 50% boost in power in an updated model that has been submitted to FDA for review.
That is strange. Wonder if that might be a mistake when the delinquent reporting status was removed?
Or maybe Collier is throwing in the towel and going pink to reduce filing fees (cheaper as Pink status).
Any word on a shareholder meeting this month?
Looks like we have some Christmas bonus money being used to buy shares today.
The sales continue to be from the same buyer.
"During the nine months ended September 30, 2023, we had one significant customer, which accounted for approximately 100% of sales."
Take a break from staring at the ZHUD Bid/Ask for the next week. Highly unlikely anything is going to happen before 2024 arrives.
Know that what you hold will generate profitable returns in due time.
Looks like we are running into some selling of shares for tax season.
Who is Paul and what does he have anything to do with TNBI? I do not see that name associated with TNBI.
Can you provide more details of what type of news we are expecting to see arrive?
We need to see some sales of the new assets they acquired earlier in the year.
Current clients of Best Energy include: KFC, Shell Oil, Secret Recipe, WATES,
7eleven, IBM, Texaco and McDonalds.
They need to reach out to these clients with the newly acquired tech and get the income rolling in.
I increased my share count yesterday.
Waiting for the eventual reveal.
8K released.
https://www.otcmarkets.com/filing/html?id=17109234&guid=UgJ-k6uprzMS3Yh
Below is a portion of it and the reason for the Q3 delay.
After a comprehensive internal review, on December 4, 2023 the board of directors of the Company, together with the Company’s management, concluded that there were errors in the financial statements previously issued for the quarters ended March 31, 2023 and June 30, 2023 in our Quarterly Reports on Form 10-Q filed on May 17, 2023 and August 14, 2023, respectively. As a result, the financial statements in those reports should no longer be relied upon.
Poor stockholders getting teased once again that a Bid may actually appear. Once it gets close, the Ask will be reloaded with more 1s.
Happens time after time.
Strange. Shows as .025 transaction on the time and sales.
Is there a way to know if any social media ads/coupons are driven by YSO?
Does YSO have a tag of some sort on the coupons/ads?
We are going to encounter impatient traders if Belisarian continues their silence of any updates.
It is the way of life of the OTC.
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's asset valuation acceptable to the Endonovo board. It was further agreed, that SofPulse, Inc. will prepare to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.
To fuel SofPulse, Inc. operations, the company aims to conduct a capital raise of up to $500,000 through a 506 offering tailored for accredited investors. At a pre-money valuation of $10 million and shares priced at $2.50 per share, the capital raise is anticipated to support further development and growth.
"The acquisition of the SofPulse® assets is a major step in the ongoing transformation of the SofPulse® brand, as we execute our strategic priorities, intensifying our focus and augments the value for all our shareholders.": commented, Ira Weisberg, President of SofPulse, Inc.
Valuation
In 2018, the ENDV-valued assets to be purchased by SofPulse, Inc. were valued at $75 million by a third-party valuation firm. As a condition of the announced sale of the SofPulse® assets, it was agreed that they would update the previous valuation with a qualified third party acceptable to both the Endonovo’s board and SofPulse, Inc., to establish the purchase price.
Upon signing of the definitive agreement, the sole ENDV board member shall receive super majority voting rights in preferred shares until the entire acquisition price is fulfilled.
Stock Issuance to Endonovo Shareholders
As consideration for the purchase from Endonovo, SofPulse Inc. shall issue $50 million in restricted stock, priced at $5.00 per share. Approximately 80% of the issuance shall be issued ENDV’s shareholders for this transaction, either as a stock dividend or through an alternative mechanism.
In addition to the stock issuance, SofPulse, Inc. has agreed to pay ENDV any additional sum assessed by a third-party valuation report (estimated to be between $50,000,000 to $100,000,000). This payment will initially be paid through a senior note which can be paid in cash or marketable securities listed on NASDAQ after the third-party evaluation concludes.
ENDV will continue the operations of its mergers and acquisitions division, its telehealth division (which SofPulse has agreed to be a customer with a five-year contract), and the further development of its non-medical device business.
Purchase Price Settlement and Capital Raise
The remaining purchase price owed to ENDV will be resolved through a secured promissory which will be convertible into NASDAQ listed marketable securities at the sole discretion of the Seller.
The transaction is anticipated to conclude on December 31, 2023, pending the customary regulatory approvals and satisfaction of other closing conditions. These include the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act.
Future Outlook and Expansion Plans
Upon acquisition, SofPulse, Inc. is set to explore an assortment of growth opportunities. The company's strategic vision encompasses numerous initiatives aimed at swift and substantial revenue expansion.
"By expanding SofPulse® VA and Department of Defense contracts through the Federal Supply Schedule, developing a comprehensive telehealth platform through Endonovo’s technology, growing both domestic and international surgical and pain management markets, alongside robust research and development strategies, SofPulse Inc. is strategically positioned to leverage the commercialization of SofPulse® brand assets and IP. Focusing on sales and marketing efforts to expand these programs and venturing into new consumer markets, SofPulse® is geared towards reaching annualized revenues of approximately $100 million by 2025. ": Weisberg concluded.
ENDV purchased the Sofpulse assets from Rio Grande for $4.5M and now it is worth $50M ?
Alrighty then! This does not quite pass the smell test.
8K announcement.
On December 3, 2023, the Company entered into a definitive Asset Purchase Agreement with SofPulse, Inc., a Delaware corporation ("SPI"), to acquire the SofPulse® Assets which represents the technology, both patented and proprietary, inventories and contract rights relating to the Company's SofPulse® Electroceutical® device as it relates to medical use. The Company has retained rights to the non-medical applications of SofPulse® and will continue the development of its tele-health business. The purchase price under the Asset Purchase Agreement shall be no less then $50 Million and shall be fixed to equal the amount of a third party evaluation of the SofPulse® Assets which will be completed before the closing under the Asset Purchase Agreement. $50 Million of the purchase price for the SofPulse® Assets will be paid by the issuance of SPI stock to the Company tentatively valued at $5 a share but to be adjusted to be equal to the per share price in SPI's IPO (which may or may not ever occur) and the balance to be in the form of cash or note. The Closing under the Asset Purchase Agreement is subject to shareholder approval by the Company and other conditions.The foregoing is only a summary of the Asset Purchase Agreement and the reader is referred to the agreement, which is an exhibit to this report for its full terms and conditions.
Has anyone contacted the company to inquire why they have not released Q3 earnings?
This is not a good look for an OTCQB listed company to be extremely past due with the Q ER.
Well....that explains the selling of shares today. LOL